Northside Hospital’s Blood and Marrow Transplant (BMT) Program has again ranked among the best in the United States for bone marrow transplant survival outcomes. For the 16th consecutive year (2009-24), Northside’s program exceeded predicted one-year survival outcomes for U.S. transplant centers, according to the 2024 Transplant Center Survival Report by the Centers for International Blood and Marrow Transplant Research (CIBMTR). Northside is the only U.S. transplant program to achieve this historic milestone. 

Each year, CIBMTR analyzes survival data for U.S. transplant centers performing allogeneic transplants, providing an overall risk-adjusted analysis indicating whether one-year survival is as expected, above expected or below expected for each specific transplant center compared to an average transplant center. CIBMTR’s 2024 report tabulated patient survival following transplantation at 172 adult and pediatric transplant centers for the reporting cycle of Jan. 1, 2020-Dec. 31, 2022. Patients at Northside had an 82.6% one-year survival rate, placing the program in the top 95th percentile for risk-adjusted survival outcomes.

Northside is the only center in Georgia to achieve outcomes statistically superior to predicted rates, and one of just 12 U.S. centers (less than 10% of all centers) to earn this designation in the latest reporting cycle.

The full news release is available at: https://www.northside.com/about/news-center/articles/2025/02/18/northside-bmt-exceeds-survival-expectations-16-years-running